8-K: Interpace Biosciences Announces Restructuring Plan Following Medicare Coverage Decision

Interpace Biosciences implements a restructuring plan to mitigate the financial impact of Medicare's decision to end reimbursement for its PancraGEN test.

Summary

• Interpace Biosciences announced a restructuring plan in response to the Genetic Testing for Oncology (L39365) Local Coverage Determination (LCD) issued by Medicare Administrative Contractor Novitas Solutions, which ends reimbursement for the company's PancraGEN test.
• Specimen acceptance for first-line fluid chemistry and PancraGEN testing will cease after May 2, 2025.
• The restructuring plan includes workforce reduction and is expected to be substantially completed by the end of the second quarter of 2025.
• The company anticipates incurring severance costs between $0.5 million and $0.6 million in the second quarter of 2025, in addition to the $0.2 million already recorded in the first quarter of 2025.
• The company expects the restructuring to reduce annualized cost of revenue and operating expenses by approximately $12.5 million to $14.5 million.
• This cost reduction is projected to substantially offset the anticipated loss of approximately one-third of its revenues.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the loss of Medicare reimbursement and the resulting restructuring plan, including workforce reductions. However, the company is taking steps to mitigate the financial impact.

Positives

• The restructuring plan is expected to substantially offset the loss of approximately one-third of the company's revenues.
• The company expects annualized cost of revenue and operating expenses to be reduced by approximately $12.5 million to $14.5 million.

Negatives

• Medicare will no longer reimburse Interpace Biosciences' PancraGEN test.
• The company is reducing its workforce as part of the restructuring plan.
• The company expects to lose approximately one-third of its revenues.

Risks

• The cost estimates associated with the restructuring plan are subject to assumptions, and actual results may differ materially.
• The company may incur additional costs not currently contemplated due to events associated with the restructuring plan.

Future Outlook

The company expects the restructuring plan to substantially offset the loss of approximately one-third of its revenues and reduce annualized cost of revenue and operating expenses by approximately $12.5 million to $14.5 million.

Management Comments

• The company announced implementation of its previously approved restructuring and cost-savings plan to reduce operating costs and better align its workforce with the loss of PancraGEN.

Industry Context

The announcement reflects the challenges faced by diagnostic companies when Medicare coverage policies change, forcing them to adapt their cost structures and business strategies.

Comparison to Industry Standards

• Other diagnostic companies facing similar reimbursement challenges, such as Exact Sciences with its Cologuard test or Genomic Health (now part of Exact Sciences) with its Oncotype DX test, have had to navigate changing coverage policies and demonstrate clinical utility to maintain reimbursement.
• These companies often engage in extensive lobbying and clinical studies to support their tests' value proposition to payers.
• The magnitude of Interpace's cost reduction efforts and revenue impact should be compared to similar companies undergoing restructuring due to reimbursement changes to assess its relative severity and strategic response.

Stakeholder Impact

• Shareholders will be impacted by the loss of revenue and the restructuring plan.
• Employees will be impacted by the workforce reduction.
• Customers may experience changes in service or product availability.

Next Steps

• Substantial completion of the Restructuring Plan by the end of the second quarter of 2025.

Key Dates

Keywords

PancraGEN, restructuring, Medicare, reimbursement, Interpace Biosciences, cost savings, workforce reduction, LCD, Novitas Solutions